According to filings with the U.S. Securities and Exchange Commission, Procyrion is raising up to $64,000,835.00 in new funding. Sources indicate that as part of senior management President and Chief Executive Officer, Eric Fain played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Procyrion
Procyrion is dedicated to improving outcomes for patients with cardiac and renal impairment using its catheter-deployed pump technology to address conditions with significant unmet needs. Aortix is a percutaneous mechanical circulatory support device that treats cardiorenal syndrome with a rapidly-deployed intra-aortic catheter-based system. Aortix is currently in the research and development phase and is not available for sale in any country. (Caution: investigational device. Limited by federal law to investigational use.).

To learn more about Procyrion, visit http://www.procyrion.com/

Contact:
Eric Fain, President and Chief Executive Officer
713-579-9227
https://www.linkedin.com/in/eric-fain-149408b/

SOURCE: http://www.intelligence360.io
Copyright (c) 2024 SI360 Inc. All rights reserved.